CARMELO DIAZ: Open Payments
NPI 1326420217 · SALT LAKE CITY, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,774 in 151 payments from 17 companies in 2025. Trend: 2023 $2,788 · 2024 $3,587 · 2025 $2,774
Food & beverage: $2,774
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 17 | $361 |
| Incyte Corporation | 20 | $347 |
| Verrica Pharmaceuticals Inc. | 35 | $307 |
| Arcutis Biotherapeutics, Inc. | 21 | $281 |
| ABBVIE INC. | 17 | $276 |
| Janssen Scientific Affairs, LLC | 3 | $234 |
| Amgen Inc. | 9 | $207 |
| LEO Pharma Inc. | 8 | $138 |
| GENZYME CORPORATION | 5 | $118 |
| E.R. Squibb & Sons, L.L.C. | 1 | $115 |
Products named: TREMFYA, OPZELURA, YCANTH, Zoryve, DUPIXENT, RINVOQ, SKYRIZI, OTEZLA.
Industry payments across UT — which companies pay providers there.
